Abstract
Nitric oxide (NO) produced by endothelial NO synthase (eNOS) represents an anti-atherosclerotic principle. NO bioavailability is decreased in atherosclerosis due to increased NO inactivation by reactive oxygen species and reduced NO synthesis. Various types of vascular pathophysiology are associated with oxidative stress, with NADPH oxidases as the major source of reactive oxygen species. These inactivate NO. Also, oxidative stress is likely to be the main cause for oxidation of the essential NOS cofactor, tetrahydrobiopterin (BH4). A lack of BH4 leads to eNOS uncoupling (i.e., uncoupling of oxygen reduction from NO synthesis in eNOS). Based on these pathomechanisms, the therapeutic potential of a number of compounds is discussed in this review: (1) NO donors; (2) L-arginine; (3) folic acid; (4) BH4 and its precursor sepiapterin; (5) compounds that upregulate eNOS and concomitantly maintain eNOS activity (e.g. midostaurin, betulinic acid, ursolic acid, AVE9488 and AVE3085); (6) compounds that enhance the de novo synthesis of BH4 by stimulating expression or activity of GTP cyclohydrolase I; and (7) 3-hydroxy-3-methylglutarylcoenzyme A inhibitors (statins) and drugs interrupting the renin-angiotensin-aldosterone system. Statins, angiotensin II type 1 receptor blockers, angiotensin-converting enzyme (ACE) inhibitors, the aldosterone antagonist eplerenone and the renin inhibitor aliskiren enhance NO bioactivity and reduce atherosclerosis progression through multiple mechanisms.
Keywords: Nitric oxide, atherosclerosis, endothelial dysfunction, eNOS uncoupling, tetrahydrobiopterin
Current Pharmaceutical Design
Title: Prevention of Atherosclerosis by Interference with the Vascular Nitric Oxide System
Volume: 15 Issue: 27
Author(s): Huige Li and Ulrich Forstermann
Affiliation:
Keywords: Nitric oxide, atherosclerosis, endothelial dysfunction, eNOS uncoupling, tetrahydrobiopterin
Abstract: Nitric oxide (NO) produced by endothelial NO synthase (eNOS) represents an anti-atherosclerotic principle. NO bioavailability is decreased in atherosclerosis due to increased NO inactivation by reactive oxygen species and reduced NO synthesis. Various types of vascular pathophysiology are associated with oxidative stress, with NADPH oxidases as the major source of reactive oxygen species. These inactivate NO. Also, oxidative stress is likely to be the main cause for oxidation of the essential NOS cofactor, tetrahydrobiopterin (BH4). A lack of BH4 leads to eNOS uncoupling (i.e., uncoupling of oxygen reduction from NO synthesis in eNOS). Based on these pathomechanisms, the therapeutic potential of a number of compounds is discussed in this review: (1) NO donors; (2) L-arginine; (3) folic acid; (4) BH4 and its precursor sepiapterin; (5) compounds that upregulate eNOS and concomitantly maintain eNOS activity (e.g. midostaurin, betulinic acid, ursolic acid, AVE9488 and AVE3085); (6) compounds that enhance the de novo synthesis of BH4 by stimulating expression or activity of GTP cyclohydrolase I; and (7) 3-hydroxy-3-methylglutarylcoenzyme A inhibitors (statins) and drugs interrupting the renin-angiotensin-aldosterone system. Statins, angiotensin II type 1 receptor blockers, angiotensin-converting enzyme (ACE) inhibitors, the aldosterone antagonist eplerenone and the renin inhibitor aliskiren enhance NO bioactivity and reduce atherosclerosis progression through multiple mechanisms.
Export Options
About this article
Cite this article as:
Li Huige and Forstermann Ulrich, Prevention of Atherosclerosis by Interference with the Vascular Nitric Oxide System, Current Pharmaceutical Design 2009; 15 (27) . https://dx.doi.org/10.2174/138161209789058002
DOI https://dx.doi.org/10.2174/138161209789058002 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?
Current Pharmaceutical Design Chagas Disease Chemotherapy: What Do We Know So Far?
Current Pharmaceutical Design Expression of microRNAs (133b and 138) and Correlation with Echocardiographic Parameters in Patients with Alcoholic Cardiomyopathy
MicroRNA Pathogenesis of Age-Related Cataract: A Systematic Review of Proteomic Studies
Current Proteomics Matrix Metalloproteinases: Drug Targets for Myocardial Infarction
Current Drug Targets Protein Kinase CK2 in Human Diseases
Current Medicinal Chemistry Alcohol and the Cardiovascular System: A Double-Edged Sword
Current Pharmaceutical Design Stem Cells as In Vitro Models of Disease
Current Stem Cell Research & Therapy Coenzyme Q10 in Neuromuscular and Neurodegenerative Disorders
Current Drug Targets Aldose Reductase, Still a Compelling Target for Diabetic Neuropathy
Current Drug Targets Terminalia arjuna in Cardiovascular Diseases: Making the Transition from Traditional to Modern Medicine in India
Current Pharmaceutical Biotechnology Meet Our Editorial Board Member
Current Vascular Pharmacology Heart Failure in North America
Current Cardiology Reviews Mitochondrially Targeted Antioxidants for the Treatment of Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Human Heart Failure: A Proteomics Perspective
Current Proteomics The Effect of GLUT1 on the Survival Rate and Immune Cell Infiltration of Lung Adenocarcinoma and Squamous Cell Carcinoma: A Meta and Bioinformatics Analysis
Anti-Cancer Agents in Medicinal Chemistry Proteome and Metabolome Alterations in Heart and Liver Indicate Compromised Energy Production During Sepsis
Protein & Peptide Letters Aging as an Evolvability-Increasing Program Which can be Switched Off by Organism to Mobilize Additional Resources for Survival
Current Aging Science Autophagy and Mitochondria in Obesity and Type 2 Diabetes
Current Diabetes Reviews mTOR in Growth and Protection of Hypertrophying Myocardium
Cardiovascular & Hematological Agents in Medicinal Chemistry